ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 607,71
0,50%
Dow Jones
38 834,86
0,15%
DAX
18 177,77
0,61%
Brent Oil
84,595
-0,12%
Bitcoin
65 795,62
1,27%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Arcutis Biotherapeutics Inc (ARQT)

  7. Arcutis Biotherapeutics Inc (ARQT) Actualités

ARQT Arcutis Biotherapeutics Inc

8,15
0,00 (0,00%)
Avant marché
Dernière mise à jour : 10:06:48
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Arcutis Biotherapeutics Inc ARQT NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 8,15 10:06:48
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
8,15
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
18/6/202422:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/6/202422:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/6/202422:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/6/202422:47EDGAR2Form 8-K - Current report
10/6/202420:30GLOBEArcutis Announces New Long-Term Data of Roflumilast Cream..
06/6/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/6/202422:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
05/6/202414:00GLOBEArcutis Announces Multiple Abstracts, Including Oral..
04/6/202420:03EDGAR2Form 144 - Report of proposed sale of securities
03/6/202414:00GLOBEArcutis to Present at the Goldman Sachs 45th Annual Global..
30/5/202401:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/5/202421:54EDGAR2Form 144 - Report of proposed sale of securities
28/5/202413:00PRNCAArcutis Canada annonce l'acceptation aux fins d'examen par..
20/5/202423:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202421:58EDGAR2Form 144 - Report of proposed sale of securities
14/5/202422:06EDGAR2Form 8-K - Current report
14/5/202422:00GLOBEArcutis Announces First Quarter 2024 Financial Results and..
14/5/202413:18IHMARKETNEWSUS Futures Remain Steady Amid Wall Street Caution Ahead of..
13/5/202414:00GLOBEExpert Panel Review Further Validates Use of ZORYVE®..
03/5/202422:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
29/4/202422:00GLOBEArcutis to Report First Quarter 2024 Financial Results..
10/4/202414:00GLOBEArcutis Appoints David Topper as Chief Financial Officer
05/4/202422:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
01/4/202413:00GLOBESol-Gel’s Collaboration Partner First-to-File ANDA Drug..
28/3/202413:00GLOBEArcutis to Present at the 23rd Annual Needham Virtual..
11/3/202413:00GLOBEArcutis Promotes Todd Tucker to Chief Human Resources..
10/3/202421:00GLOBEArcutis Presents Late-Breaking Data From INTEGUMENT-PED..
09/3/202422:00GLOBENew Research Reveals Genomic Profile of Seborrheic..
06/3/202423:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202423:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202423:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202422:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
04/3/202423:47EDGAR2Form 144 - Report of proposed sale of securities
04/3/202423:42EDGAR2Form 144 - Report of proposed sale of securities
04/3/202423:40EDGAR2Form 144 - Report of proposed sale of securities
04/3/202422:10EDGAR2Form 8-K - Current report
04/3/202422:00GLOBEArcutis Announces Closing of Public Offering of Common Stock..
04/3/202414:00GLOBEArcutis Announces Acceptance of Late Breaking Abstract in..
01/3/202422:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202422:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/2/202423:00GLOBEArcutis to Present at the TD Cowen 44th Annual Health Care..
29/2/202405:30GLOBEArcutis Announces Pricing of $150 Million Public Offering
28/2/202422:54EDGAR2Form 144 - Report of proposed sale of securities
28/2/202422:21EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28/2/202422:10EDGAR2Form 8-K - Current report
28/2/202422:10GLOBEArcutis Announces Proposed Public Offering
28/2/202422:00GLOBEArcutis and Sato Announce Strategic Collaboration and..
27/2/202422:34EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202413:48EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202413:44EDGAR2Form 8-K - Current report

Dernières Valeurs Consultées

NASDAQ
ARQT
Arcutis Biotherapeutics
ASX
WOWCD
Woolworths
USOTC
SCLTF
Searchlight Resources (QB)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés